)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Zynex
Zynex (ZYXI) investor relations material
Zynex has been delisted
Zynex Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary18 Nov, 2025
Executive summary
New management and board members have been appointed, including leaders in sales, legal, compliance, regulatory, HR, billing, and strategic marketing, as well as two new directors overseeing audit and strategic alternatives.
A three-part turnaround strategy is underway: compliance, liquidity improvement, and revenue/cash flow enhancement.
Major impairment charges of $30.7M were recorded in Q3 2025 related to the ZMS subsidiary.
Significant operational disruptions due to Tricare payment suspension and workforce reductions.
Province LLC and a Special Committee were engaged to evaluate strategic and financing alternatives, with no transaction identified yet.
Financial highlights
Net revenue for Q3 2025 was $13.4M, down from $50M in Q3 2024, mainly due to Tricare payment suspension and payer claim issues.
Gross profit was $8.1M (60% margin), compared to $39.8M (80% margin) in Q3 2024.
Net loss for Q3 2025 was $42.9M ($1.42 per share), versus net income of $2.4M in Q3 2024.
Adjusted EBITDA loss was $12.3M, compared to positive $5.1M in Q3 2024.
Cash and cash equivalents stood at $13.3M as of September 30, 2025.
Outlook and guidance
Management is focused on resolving government investigations, recapitalizing, and improving operational performance.
Substantial doubt exists about the ability to continue as a going concern for 12 months from the financial statement issuance date.
The company is exploring restructuring and financing alternatives, including discussions with creditors.
No specific financial guidance provided.
Early signs of stabilization in order volumes and improved sales force productivity are noted.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Zynex
- $100 million shelf registration targets growth in pain management and patient monitoring devices.ZYXI
Registration Filing - Director elections, auditor ratification, and strong governance are key meeting topics.ZYXIProxy Filing
- Shareholders will vote on director elections and auditor ratification at the May 2025 meeting.ZYXIProxy Filing
- Q2 2025 revenue fell 55% and net loss reached $20M amid Tricare suspension and restructuring.ZYXIQ2 2025
- Q3 2024 revenue flat at $50M, 13% order growth, 2024 revenue outlook raised to $200M.ZYXIQ3 2024
- Sales force productivity and new device launches drive growth, with major FDA milestones ahead.ZYXIH.C. Wainwright 26th Annual Global Investment Conference 2024
- Q2 revenue up 11% to $49.9M, but net income fell as expenses and product mix shifted.ZYXIQ2 2024
- Q1 2025 revenue fell 43% to $26.6M, with cost cuts and new product plans amid TRICARE suspension.ZYXIQ1 2025
- Tricare payment suspension led to Q4 loss; cost cuts and new products aim for 2025 recovery.ZYXIQ4 2024
Zynex
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Zynex, Inc. focuses on the design, manufacture, and marketing of medical devices for the electrotherapy market. It offers NexWave for acute chronic pain management; NeuroMove for activation and exercise of muscles for rehabilitative purposes related to stroke, spinal cord injuries and other neurological disorders; and InWave, an electrical muscle stimulator that treats female urinary incontinence. The company sells its products through distributors in the United States and internationally to hospitals, physical therapy clinics, pain management clinics, home health agencies, long-term care facilities, assisted living facilities, rehabilitation clinics and physician offices. The company was founded in 1996 and is headquartered in Englewood, Colorado.